Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis
Michelle Leech(Monash Institute of Medical Research), Eric F. Morand(Novartis (Switzerland)), Leilani L. Santos(Royal Women's Hospital), Ernst J. Wolvetang(The University of Queensland), Paul Hutchinson(National University of Singapore), John R. David(Harvard University), Derek Lacey(Monash Medical Centre), Jin Xue(Monash Medical Centre), Richard Bucala(Yale University)
Cited by 112
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites
|The Journal of Immunology|2001|957
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726